PHARMD | USMLE STEP 1 & 2 CK | NAPLEX | BCPS | NR 565 | 2026/2027 ACADEMIC CYCLE
THE ULTIMATE ANTIMICROBIAL BUG-DRUG SPECTRUM MATRIX &
EMPIRIC THERAPY GUIDE
Curriculum Alignment: Doctor of Pharmacy (Pharm.D), Medical (MD/DO) & APRN | Aligned Texts: Katzung's Basic & Clinical
Pharmacology, Lippincott Illustrated Reviews & IDSA 2026/2027 Clinical Practice Guidelines
Legal & Authorship Disclaimer: Independently authored educational synthesis and original clinical practice bank created for
academic revision during the 2026/2027 cycle. Not affiliated with or reproduced from any proprietary university exam or testing
board. All scenarios, tables, and rationales are 100% original clinical formulations.
DOCUMENT ARCHITECTURE (PAGES 1–12): Mod 1: Cellular Targets, Bactericidal vs. Bacteriostatic & Resistance Mechanisms
(p. 2) • Mod 2: Master 2D Bug-Drug Spectrum Matrix (p. 3) • Mod 3: PK/PD Indices, Vancomycin AUC/MIC & Aminoglycoside TDM
+ Renal Exceptions (p. 4) • Mod 4: 10 High-Yield IDSA Empiric Clinical Prescribing Algorithms (p. 5) • Mod 5: Signature Toxicities,
Black Box Warnings & CYP450 Traps (p. 6) • Mod 6: 25-Question Board-Style Clinical Vignette Exam Bank with Full Distractor
Rationales (p. 7–12).
PREVIEW HOOK: HIGH-ALERT EMPIRIC VS. CONTRAINDICATED ANTIMICROBIAL PRESCRIBING MATRIX
Clinical Syndrome 1st-Line Empiric Exact Mechanism of Contraindications & Mandatory TDM &
Regimen Action Black Box Labs
MRSA Bacteremia / 1st Line Vancomycin IV Vanc: Binds D-Ala-D-Ala CONTRAINDICATED Vanc: AUC24/MIC
Endocarditis or Daptomycin 8–10 terminus → blocks Never use Daptomycin 400–600 mg·h/L;
(Invasive Gram+) mg/kg IV q24h transglycosylation. in pneumonia SCr.
Dapto: Ca2+-dependent (inactivated by Dapto: Baseline &
membrane depolarization. pulmonary surfactant weekly Serum CK
lipids). Avoid Vanc + (myopathy).
Pip/Tazo (AKI).
HAP / VAP 1st Line Cefepime 2g β-Lactams: Acylate PBPs BLACK BOX Sputum/blood
(Nosocomial / ICU q8h (or Meropenem) + → block peptidoglycan Linezolid + cultures; CBC weekly
Ventilator) Vancomycin (or cross-linking. SSRIs/SNRIs triggers if Linezolid >14d
Linezolid) Linezolid: Binds 50S (23S fatal Serotonin (thrombocytopenia);
rRNA) → blocks 70S Syndrome (reversible renal panel.
initiation. non-selective MAOI).
Carbapenem- KPC: 1st Line Avibactam: EXAM TRAP Carbapenemase
Resistant (CRE) Ceftazidime/Avibactam Diazabicyclooctane inhibits Avibactam, PCR/phenotypic
(KPC vs. NDM-1) NDM-1 (Metallo): Ambler Class A/C/D. Vaborbactam & testing; CrCl for dose
Cefiderocol Cefiderocol: Siderophore Relebactam have ZERO adjustment; LFTs.
iron-transport PBP3 activity against Ambler
inhibitor. Class B Metallo-β-
lactamases (NDM).
Fulminant C. 1st Line Fidaxomicin: Inhibits FATAL TRAP IV WBC (≥15,000 =
difficile Colitis OralFidaxomicin (Initial) bacterial RNA polymerase Vancomycin does NOT severe), SCr (≥1.5 =
(Shock / Megacolon) Fulminant: PO sigma subunit. cross into the gut lumen severe), stool toxin
Vancomycin 500mg QID Metro: PFOR-reduced and is 100% ineffective EIA/NAAT, abdominal
+ IV Metronidazole nitro free-radical DNA for C. diff colitis. X-ray.
strand breaks.
PREVIEW SOLVED VIGNETTE: A 64-year-old male in the ICU with ventilator-associated pneumonia (MRSA +
Pseudomonas risk) and major depression (on Sertraline 100 mg daily) has Stage 4 CKD (eGFR 22 mL/min).
Which anti-MRSA agent is safest, and why are two other common MRSA options contraindicated?
• Verified Clinical Rationale: Initiate renally-adjusted IV Vancomycin (guided by AUC24/MIC 400–600 target) or
Ceftaroline. Daptomycin is strictly contraindicated because pulmonary surfactant phospholipids sequester and inactivate
the lipopeptide in alveolar fluid. Linezolid (although requiring zero renal adjustment) is contraindicated with active
Sertraline therapy because Linezolid inhibits Monoamine Oxidase (MAO-A/B), precipitating life-threatening Serotonin
Syndrome (clonus, hyperthermia, autonomic instability).
The Ultimate Antimicrobial Bug-Drug Spectrum Matrix & Empiric Therapy Guide (2026/2027) Page 1 of 12
, MODULE 1: CELLULAR TARGET ARCHITECTURE & RESISTANCE MECHANISMS
FIGURE 1.1: PROKARYOTIC CELLULAR TARGET MAP & RIBOSOMAL / ENZYMATIC BLOCKADE SITES
1. CELL WALL & MEMBRANE 2. RIBOSOMES (30S vs. 50S) 3. DNA / RNA REPLICATION 4. FOLATE ANTIMETABOLITES
• β-Lactams: Block PBP transpeptidase • 30S ("Buy AT 30"): Aminoglycosides • Fluoroquinolones: Inhibit DNA • PABA + Pteridine (Step 1):
• Vancomycin: Binds D-Ala-D-Ala (16S cidal misreading), Tetracyclines Gyrase (Topo II) & Topoisomerase IV Sulfamethoxazole blocks
• Fosfomycin: Inhibits MurA enzyme • 50S ("CCEL at 50"): Macrolides (23S), • Rifampin / Fidaxomicin: Inhibit Dihydropteroate Synthase (DHPS)
• Daptomycin: Ca²⁺ depolarization Clindamycin, Linezolid (70S init), DNA-dependent RNA Polymerase • Dihydrofolate → THF (Step 2):
• Colistin: Disrupts LPS Lipid A Chloramphenicol (peptidyl transf.) • Metronidazole: Free radical DNA break Trimethoprim blocks DHFR
1. AMBLER CLASSIFICATION OF BETA-LACTAMASES & HIGH-YIELD GENETIC RESISTANCE TRAPS
Resistance Class Representative
Enzymes / Gene
Substrates Hydrolyzed
(Destroyed)
Inhibited By (Active
BLIs) Drug of Choice (DOC)
Ambler Class A: Plasmid CTX-M, TEM, Penicillins, 1st–4th Gen Clavulanate, 1st Line Meropenem or
ESBL SHV (E. coli, Cephalosporins Tazobactam, Avibactam, Ertapenem (avoid
Klebsiella) (Ceftriaxone, Cefepime), Vaborbactam Pip/Tazo in severe
Aztreonam bacteremia)
Ambler Class A: Klebsiella pneumoniae ALL standard β-lactams Avibactam, 1st Line
KPC carbapenemase including Meropenem, Vaborbactam, Ceftazidime/Avibactam or
(Serine) Imipenem, Ertapenem, Relebactam (NOT Meropenem/Vaborbactam
Cefepime Clav/Tazo)
Ambler Class B: NDM-1, VIM, IMP Penicillins, NONE of the standard 1st Line Cefiderocol or
Metallo (MBL) (Requires active-site Cephalosporins, BLIs Ceftazidime/Avibactam +
Zn2+ ion) Carbapenems. (Spares (Avibactam/Vaborbactam Aztreonam
Aztreonam monomer) fail)
Ambler Class C: Chromosomal inducible 1st–3rd Gen Cephs Avibactam (Clavulanate 1st Line Cefepime
AmpC ampC ("SPACE" bugs) (Ceftriaxone induces & Tazobactam fail to (zwitterion resists
derepression), BL/BLIs, inhibit) hydrolysis) or Meropenem
Aztreonam
Ambler Class D: OXA-48 Penicillins and Avibactam (inhibits 1st Line
OXA (Enterobacterales), Carbapenems (variable OXA-48; Vaborbactam & Ceftazidime/Avibactam or
OXA-23 3rd/4th Gen Relebactam fail) Cefiderocol
(Acinetobacter) Cephalosporin hydrolysis)
MRSA vs. VRE MRSA: chromosomal MRSA: PBP2a lowers Enzymatic BLIs have MRSA: Vancomycin,
Target Shift mecA affinity for β-lactams. zero effect on PBP2a or Daptomycin, Ceftaroline.
VRE: plasmid vanA / VRE: D-Ala-D-Ala mutates D-Ala-D-Lac VRE: Daptomycin or
vanB to D-Ala-D-Lactate. Linezolid.
2. CORE MICROBIOLOGICAL RULES & EXAM TRAPS
Inducible Chromosomal AmpC ("SPACE / HECK-Yes" Pathogens): Serratia marcescens, Providencia, Aeromonas,
Citrobacter freundii, Enterobacter cloacae, Klebsiella aerogenes, and Morganella. CLINICAL TRAP Even if initial lab
susceptibilities report Ceftriaxone or Ceftazidime as "Susceptible," 3rd-generation cephalosporins select for ampD
regulatory mutations during therapy, causing frank clinical failure. Treat serious infections with Cefepime or a
Carbapenem.
Inducible Clindamycin Resistance (The "D-Test" / erm Gene): Methylation of the 23S rRNA binding site via plasmid
erm genes confers resistance to Macrolides, Clindamycin, and Streptogramin B (MLSB phenotype). If a S. aureus
isolate is Erythromycin-Resistant and Clindamycin-Susceptible, perform a D-zone disk diffusion test; a flattened "D"
zone indicates inducible resistance—do not use Clindamycin.
LAME Organisms (Inherently Resistant to ALL Cephalosporins — Except Ceftaroline for MRSA/E. faecalis):
Listeria monocytogenes (use Ampicillin or TMP-SMX), Atypicals (Mycoplasma, Chlamydia, Legionella — lack
peptidoglycan or are intracellular; use Macrolide/Doxy/FQ), MRSA (use Vancomycin/Daptomycin/Ceftaroline), and
Enterococci (E. faecalis = Ampicillin; E. faecium = Daptomycin/Linezolid).
The Ultimate Antimicrobial Bug-Drug Spectrum Matrix & Empiric Therapy Guide (2026/2027) Page 2 of 12
THE ULTIMATE ANTIMICROBIAL BUG-DRUG SPECTRUM MATRIX &
EMPIRIC THERAPY GUIDE
Curriculum Alignment: Doctor of Pharmacy (Pharm.D), Medical (MD/DO) & APRN | Aligned Texts: Katzung's Basic & Clinical
Pharmacology, Lippincott Illustrated Reviews & IDSA 2026/2027 Clinical Practice Guidelines
Legal & Authorship Disclaimer: Independently authored educational synthesis and original clinical practice bank created for
academic revision during the 2026/2027 cycle. Not affiliated with or reproduced from any proprietary university exam or testing
board. All scenarios, tables, and rationales are 100% original clinical formulations.
DOCUMENT ARCHITECTURE (PAGES 1–12): Mod 1: Cellular Targets, Bactericidal vs. Bacteriostatic & Resistance Mechanisms
(p. 2) • Mod 2: Master 2D Bug-Drug Spectrum Matrix (p. 3) • Mod 3: PK/PD Indices, Vancomycin AUC/MIC & Aminoglycoside TDM
+ Renal Exceptions (p. 4) • Mod 4: 10 High-Yield IDSA Empiric Clinical Prescribing Algorithms (p. 5) • Mod 5: Signature Toxicities,
Black Box Warnings & CYP450 Traps (p. 6) • Mod 6: 25-Question Board-Style Clinical Vignette Exam Bank with Full Distractor
Rationales (p. 7–12).
PREVIEW HOOK: HIGH-ALERT EMPIRIC VS. CONTRAINDICATED ANTIMICROBIAL PRESCRIBING MATRIX
Clinical Syndrome 1st-Line Empiric Exact Mechanism of Contraindications & Mandatory TDM &
Regimen Action Black Box Labs
MRSA Bacteremia / 1st Line Vancomycin IV Vanc: Binds D-Ala-D-Ala CONTRAINDICATED Vanc: AUC24/MIC
Endocarditis or Daptomycin 8–10 terminus → blocks Never use Daptomycin 400–600 mg·h/L;
(Invasive Gram+) mg/kg IV q24h transglycosylation. in pneumonia SCr.
Dapto: Ca2+-dependent (inactivated by Dapto: Baseline &
membrane depolarization. pulmonary surfactant weekly Serum CK
lipids). Avoid Vanc + (myopathy).
Pip/Tazo (AKI).
HAP / VAP 1st Line Cefepime 2g β-Lactams: Acylate PBPs BLACK BOX Sputum/blood
(Nosocomial / ICU q8h (or Meropenem) + → block peptidoglycan Linezolid + cultures; CBC weekly
Ventilator) Vancomycin (or cross-linking. SSRIs/SNRIs triggers if Linezolid >14d
Linezolid) Linezolid: Binds 50S (23S fatal Serotonin (thrombocytopenia);
rRNA) → blocks 70S Syndrome (reversible renal panel.
initiation. non-selective MAOI).
Carbapenem- KPC: 1st Line Avibactam: EXAM TRAP Carbapenemase
Resistant (CRE) Ceftazidime/Avibactam Diazabicyclooctane inhibits Avibactam, PCR/phenotypic
(KPC vs. NDM-1) NDM-1 (Metallo): Ambler Class A/C/D. Vaborbactam & testing; CrCl for dose
Cefiderocol Cefiderocol: Siderophore Relebactam have ZERO adjustment; LFTs.
iron-transport PBP3 activity against Ambler
inhibitor. Class B Metallo-β-
lactamases (NDM).
Fulminant C. 1st Line Fidaxomicin: Inhibits FATAL TRAP IV WBC (≥15,000 =
difficile Colitis OralFidaxomicin (Initial) bacterial RNA polymerase Vancomycin does NOT severe), SCr (≥1.5 =
(Shock / Megacolon) Fulminant: PO sigma subunit. cross into the gut lumen severe), stool toxin
Vancomycin 500mg QID Metro: PFOR-reduced and is 100% ineffective EIA/NAAT, abdominal
+ IV Metronidazole nitro free-radical DNA for C. diff colitis. X-ray.
strand breaks.
PREVIEW SOLVED VIGNETTE: A 64-year-old male in the ICU with ventilator-associated pneumonia (MRSA +
Pseudomonas risk) and major depression (on Sertraline 100 mg daily) has Stage 4 CKD (eGFR 22 mL/min).
Which anti-MRSA agent is safest, and why are two other common MRSA options contraindicated?
• Verified Clinical Rationale: Initiate renally-adjusted IV Vancomycin (guided by AUC24/MIC 400–600 target) or
Ceftaroline. Daptomycin is strictly contraindicated because pulmonary surfactant phospholipids sequester and inactivate
the lipopeptide in alveolar fluid. Linezolid (although requiring zero renal adjustment) is contraindicated with active
Sertraline therapy because Linezolid inhibits Monoamine Oxidase (MAO-A/B), precipitating life-threatening Serotonin
Syndrome (clonus, hyperthermia, autonomic instability).
The Ultimate Antimicrobial Bug-Drug Spectrum Matrix & Empiric Therapy Guide (2026/2027) Page 1 of 12
, MODULE 1: CELLULAR TARGET ARCHITECTURE & RESISTANCE MECHANISMS
FIGURE 1.1: PROKARYOTIC CELLULAR TARGET MAP & RIBOSOMAL / ENZYMATIC BLOCKADE SITES
1. CELL WALL & MEMBRANE 2. RIBOSOMES (30S vs. 50S) 3. DNA / RNA REPLICATION 4. FOLATE ANTIMETABOLITES
• β-Lactams: Block PBP transpeptidase • 30S ("Buy AT 30"): Aminoglycosides • Fluoroquinolones: Inhibit DNA • PABA + Pteridine (Step 1):
• Vancomycin: Binds D-Ala-D-Ala (16S cidal misreading), Tetracyclines Gyrase (Topo II) & Topoisomerase IV Sulfamethoxazole blocks
• Fosfomycin: Inhibits MurA enzyme • 50S ("CCEL at 50"): Macrolides (23S), • Rifampin / Fidaxomicin: Inhibit Dihydropteroate Synthase (DHPS)
• Daptomycin: Ca²⁺ depolarization Clindamycin, Linezolid (70S init), DNA-dependent RNA Polymerase • Dihydrofolate → THF (Step 2):
• Colistin: Disrupts LPS Lipid A Chloramphenicol (peptidyl transf.) • Metronidazole: Free radical DNA break Trimethoprim blocks DHFR
1. AMBLER CLASSIFICATION OF BETA-LACTAMASES & HIGH-YIELD GENETIC RESISTANCE TRAPS
Resistance Class Representative
Enzymes / Gene
Substrates Hydrolyzed
(Destroyed)
Inhibited By (Active
BLIs) Drug of Choice (DOC)
Ambler Class A: Plasmid CTX-M, TEM, Penicillins, 1st–4th Gen Clavulanate, 1st Line Meropenem or
ESBL SHV (E. coli, Cephalosporins Tazobactam, Avibactam, Ertapenem (avoid
Klebsiella) (Ceftriaxone, Cefepime), Vaborbactam Pip/Tazo in severe
Aztreonam bacteremia)
Ambler Class A: Klebsiella pneumoniae ALL standard β-lactams Avibactam, 1st Line
KPC carbapenemase including Meropenem, Vaborbactam, Ceftazidime/Avibactam or
(Serine) Imipenem, Ertapenem, Relebactam (NOT Meropenem/Vaborbactam
Cefepime Clav/Tazo)
Ambler Class B: NDM-1, VIM, IMP Penicillins, NONE of the standard 1st Line Cefiderocol or
Metallo (MBL) (Requires active-site Cephalosporins, BLIs Ceftazidime/Avibactam +
Zn2+ ion) Carbapenems. (Spares (Avibactam/Vaborbactam Aztreonam
Aztreonam monomer) fail)
Ambler Class C: Chromosomal inducible 1st–3rd Gen Cephs Avibactam (Clavulanate 1st Line Cefepime
AmpC ampC ("SPACE" bugs) (Ceftriaxone induces & Tazobactam fail to (zwitterion resists
derepression), BL/BLIs, inhibit) hydrolysis) or Meropenem
Aztreonam
Ambler Class D: OXA-48 Penicillins and Avibactam (inhibits 1st Line
OXA (Enterobacterales), Carbapenems (variable OXA-48; Vaborbactam & Ceftazidime/Avibactam or
OXA-23 3rd/4th Gen Relebactam fail) Cefiderocol
(Acinetobacter) Cephalosporin hydrolysis)
MRSA vs. VRE MRSA: chromosomal MRSA: PBP2a lowers Enzymatic BLIs have MRSA: Vancomycin,
Target Shift mecA affinity for β-lactams. zero effect on PBP2a or Daptomycin, Ceftaroline.
VRE: plasmid vanA / VRE: D-Ala-D-Ala mutates D-Ala-D-Lac VRE: Daptomycin or
vanB to D-Ala-D-Lactate. Linezolid.
2. CORE MICROBIOLOGICAL RULES & EXAM TRAPS
Inducible Chromosomal AmpC ("SPACE / HECK-Yes" Pathogens): Serratia marcescens, Providencia, Aeromonas,
Citrobacter freundii, Enterobacter cloacae, Klebsiella aerogenes, and Morganella. CLINICAL TRAP Even if initial lab
susceptibilities report Ceftriaxone or Ceftazidime as "Susceptible," 3rd-generation cephalosporins select for ampD
regulatory mutations during therapy, causing frank clinical failure. Treat serious infections with Cefepime or a
Carbapenem.
Inducible Clindamycin Resistance (The "D-Test" / erm Gene): Methylation of the 23S rRNA binding site via plasmid
erm genes confers resistance to Macrolides, Clindamycin, and Streptogramin B (MLSB phenotype). If a S. aureus
isolate is Erythromycin-Resistant and Clindamycin-Susceptible, perform a D-zone disk diffusion test; a flattened "D"
zone indicates inducible resistance—do not use Clindamycin.
LAME Organisms (Inherently Resistant to ALL Cephalosporins — Except Ceftaroline for MRSA/E. faecalis):
Listeria monocytogenes (use Ampicillin or TMP-SMX), Atypicals (Mycoplasma, Chlamydia, Legionella — lack
peptidoglycan or are intracellular; use Macrolide/Doxy/FQ), MRSA (use Vancomycin/Daptomycin/Ceftaroline), and
Enterococci (E. faecalis = Ampicillin; E. faecium = Daptomycin/Linezolid).
The Ultimate Antimicrobial Bug-Drug Spectrum Matrix & Empiric Therapy Guide (2026/2027) Page 2 of 12
